Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis

Journal of Cystic Fibrosis

Volumn 12, Issue 6, 2013, Pages 638-643

  Wang, M ^a   Ridderberg, W ^a   Hansen, C R ^b   Hoiby N ^c   Jensen Fangel, S ^a   Olesen, H V ^a   Skov, M ^b   Lemming, L E ^a   Pressler, T ^b   Johansen, H K ^c   Norskov Lauritsen N ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Department of Paediatrics   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Achromobacter xylosoxidans; Cross infections; Eradication; MLSA; Systemic therapy

Indexed keywords

CEFTAZIDIME; COLISTIN; COTRIMOXAZOLE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ACHROMOBACTER XYLOSOXIDANS; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; CONCENTRATION RESPONSE; CYSTIC FIBROSIS; DENMARK; DRUG EFFICACY; INCIDENCE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIMARY INFECTION; RECURRENT DISEASE; RETROSPECTIVE STUDY; SPECIES DISTRIBUTION; TIME;

ACHROMOBACTER XYLOSOXIDANS; CROSS-INFECTIONS; ERADICATION; MLSA; SYSTEMIC THERAPY;

ACHROMOBACTER; ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DRUG RESISTANCE, MICROBIAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; RECURRENCE; RETROSPECTIVE STUDIES; SECONDARY PREVENTION; SPUTUM; YOUNG ADULT;

EID: 84888033472     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2013.04.013     Document Type: Article

References (31)

1. Ridderberg W., Bendstrup K.E., Olesen H.V., Jensen-Fangel S., Norskov-Lauritsen N. Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment. J Cyst Fibros Dec 2011, 10(6):466-469.
2. Pereira R.H., Carvalho-Assef A.P., Albano R.M., Folescu T.W., Jones M.C., Leao R.S., et al. Achromobacter xylosoxidans: characterization of strains in Brazilian cystic fibrosis patients. J Clin Microbiol Oct 2011, 49(10):3649-3651.
3. Spilker T., VanDamme P., Lipuma J.J. Identification and distribution of Achromobacter species in cystic fibrosis. J Cyst Fibros May 2013, 12(3):298-301.
4. Tan K., Conway S.P., Brownlee K.G., Etherington C., Peckham D.G. Alcaligenes infection in cystic fibrosis. Pediatr Pulmonol Aug 2002, 34(2):101-104.
5. De B.F., Schelstraete P., Van D.S., Haerynck F., Vaneechoutte M. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J Cyst Fibros Jan 2007, 6(1):75-78.
6. Raso T., Bianco O., Grosso B., Zucca M., Savoia D. Achromobacter xylosoxidans respiratory tract infections in cystic fibrosis patients. APMIS Sep 2008, 116(9):837-841.
7. Lambiase A., Catania M.R., Del P.M., Rossano F., Terlizzi V., Sepe A., et al. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis Aug 2011, 30(8):973-980.
8. Hansen C.R., Pressler T., Nielsen K.G., Jensen P.O., Bjarnsholt T., Hoiby N. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros Jan 2010, 9(1):51-58.
9. Ronne H.C., Pressler T., Hoiby N., Gormsen M. Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case control study. J Cyst Fibros Dec 2006, 5(4):245-251.
10. Magni A., Trancassini M., Varesi P., Iebba V., Curci A., Pecoraro C., et al. Achromobacter xylosoxidans genomic characterization and correlation of randomly amplified polymorphic DNA profiles with relevant clinical features [corrected] of cystic fibrosis patients. J Clin Microbiol Apr 2010, 48(4):1035-1039.
11. Ridderberg W., Wang M., Norskov-Lauritsen N. Multilocus sequence analysis of isolates of Achromobacter from patients with cystic fibrosis reveals infecting species other than Achromobacter xylosoxidans. J Clin Microbiol Aug 2012, 50(8):2688-2694.
12. Kosorok M.R., Zeng L., West S.E., Rock M.J., Splaingard M.L., Laxova A., et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol Oct 2001, 32(4):277-287.
13. Emerson J., Rosenfeld M., McNamara S., Ramsey B., Gibson R.L. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol Aug 2002, 34(2):91-100.
14. Valerius N.H., Koch C., Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet Sep 21 1991, 338(8769):725-726.
15. Vazquez C., Municio M., Corera M., Gaztelurrutia L., Sojo A., Vitoria J.C. Early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Acta Paediatr Mar 1993, 82(3):308-309.
16. Frederiksen B., Koch C., Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol May 1997, 23(5):330-335.
17. Cohen-Cymberknoh M., Shoseyov D., Kerem E. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med Jun 1 2011, 183(11):1463-1471.
18. European Committee on Antimicrobial Susceptibility Testing (EUCAST) [Accessed]. http://http:/www.eucast.org.
19. Spilker T., Vandamme P., Lipuma J.J. A multilocus sequence typing scheme implies population structure and reveals several putative novel Achromobacter species. J Clin Microbiol Sep 2012, 50(9):3010-3015.
20. Reik R., Spilker T., Lipuma J.J. Distribution of Burkholderia cepacia complex species among isolates recovered from persons with or without cystic fibrosis. J Clin Microbiol Jun 2005, 43(6):2926-2928.
21. France M.W., Dodd M.E., Govan J.R., Doherty C.J., Webb A.K., Jones A.M. The changing epidemiology of Burkholderia species infection at an adult cystic fibrosis centre. J Cyst Fibros Sep 2008, 7(5):368-372.
22. Lambiase A., Raia V., Del P.M., Sepe A., Carnovale V., Rossano F. Microbiology of airway disease in a cohort of patients with cystic fibrosis. BMC Infect Dis 2006, 6:4.
23. Bador J., Amoureux L., Duez J.M., Drabowicz A., Siebor E., Llanes C., et al. First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM. Antimicrob. Agents Chemother. Oct 2011, 55(10):4912-4914.
24. Fritsche T.R., Sader H.S., Stilwell M.G., Dowzicky M.J., Jones R.N. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Diagn Microbiol Infect Dis Jul 2005, 52(3):195-201.
25. Almuzara M., Limansky A., Ballerini V., Galanternik L., Famiglietti A., Vay C. In vitro susceptibility of Achromobacter spp. isolates: comparison of disk diffusion, Etest and agar dilution methods. Int J Antimicrob Agents Jan 2010, 35(1):68-71.
26. Geller D.E., Pitlick W.H., Nardella P.A., Tracewell W.G., Ramsey B.W. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest Jul 2002, 122(1):219-226.
27. Moore R.D., Lietman P.S., Smith C.R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis Jan 1987, 155(1):93-99.
28. Wiesemann H.G., Steinkamp G., Ratjen F., Bauernfeind A., Przyklenk B., Doring G., et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol Feb 1998, 25(2):88-92.
29. Ratjen F., Doring G., Nikolaizik W.H. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet Sep 22 2001, 358(9286):983-984.
30. Treggiari M.M., Retsch-Bogart G., Mayer-Hamblett N., Khan U., Kulich M., Kronmal R., et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med Sep 2011, 165(9):847-856.
31. Proesmans M., Vermeulen F., Boulanger L., Verhaegen J., De B.K. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis. J Cyst Fibros Jul 2 2012.